Organogenesis Holdings (ORGO) Cost of Revenue (2017 - 2026)

Organogenesis Holdings' Cost of Revenue history runs 10 years deep, the most recent figure standing at $25.8 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 8.64% year-over-year to $25.8 million in Q1 2026; TTM through Mar 2026 was $139.6 million, a 26.0% increase from a year earlier, with the FY2025 full-year figure at $137.5 million, up 18.82% from the prior year.
• Cost of Revenue fell to $25.8 million in Q1 2026 per ORGO's latest filing, from $49.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $49.9 million in Q4 2025 and bottomed at $23.7 million in Q1 2025.
• The 5-year median for Cost of Revenue is $26.8 million (2024), against an average of $28.9 million.
• Biggest YoY gain for Cost of Revenue was 60.76% in 2025; the steepest drop was 17.33% in 2025.
• Year by year, Cost of Revenue stood at $27.1 million in 2022, then rose by 2.43% to $27.8 million in 2023, then climbed by 11.82% to $31.1 million in 2024, then soared by 60.76% to $49.9 million in 2025, then slumped by 48.37% to $25.8 million in 2026.
• Per Business Quant, the three latest ORGO Cost of Revenue figures stand at $25.8 million (Q1 2026), $49.9 million (Q4 2025), and $36.3 million (Q3 2025).